BMEYE
Date | Investors | Amount | Round |
---|---|---|---|
N/A | Series A | ||
N/A | N/A | Series A | |
€6.0m | Series B | ||
€32.5m Valuation: €32.5m | Acquisition | ||
Total Funding | €6.0m |
Recent News about BMEYE
EditBMeye specializes in developing advanced hemodynamic monitoring solutions designed to enhance patient care through non-invasive technologies. Their core product, the Nexfin monitor, provides continuous and accurate blood pressure and cardiac output measurements without the need for invasive procedures. BMeye primarily serves healthcare providers, including hospitals and clinics, within the medical technology market. The company operates on a B2B (business-to-business) model, generating revenue through the sale of their monitoring devices and associated software. By focusing on non-invasive methods, BMeye aims to improve patient outcomes, reduce healthcare costs, and streamline clinical workflows. Their innovative approach positions them as a key player in the medical technology industry, particularly in the field of cardiovascular monitoring.
Keywords: hemodynamic monitoring, non-invasive technology, Nexfin monitor, blood pressure, cardiac output, healthcare providers, medical technology, B2B, patient outcomes, cardiovascular monitoring.